Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0989 • ACR Convergence 2022
Regulatory T Cell Defects in SLE and Therapy with a Novel IL-2 Mutein: Phase 1 Clinical Results with Efavaleukin Alfa
Nandita Sarkar¹, Xuguang Hu¹, Nadia Tchao¹, Richard Furie², Alan Kivitz³, Stanley B Cohen⁴ and Kevin Gorski⁵, ¹Amgen Inc., South San Francisco, CA, ²Northwell Health, Great Neck, NY, ³Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁴Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁵Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Regulatory T cells (Treg) are critical for maintaining self-tolerance and preventing autoimmunity, and IL-2 is essential for their development, survival and suppressive function. Defects…
Abstract Number: 1100 • ACR Convergence 2022
Racial Differences in Clinical Trial Perceptions Among a Large, Predominantly Black Cohort of Patients with Systemic Lupus Erythematosus in the Southeastern United States
Jessica Williams¹, Gaobin Bao¹, Charmayne Dunlop-Thomas², Cristina Drenkard², Kim Schofield¹ and S. Sam Lim², ¹Emory University School of Medicine, Atlanta, GA, ²Emory University, Atlanta, GA
Background/Purpose: Black patients have higher incidence and severity of systemic lupus erythematosus (SLE) and worse outcomes as compared to White patients, yet Black patients are…
Abstract Number: 1275 • ACR Convergence 2022
Pneumococcal Vaccination Compliance Rate Among Lupus and Rheumatoid Arthritis Patients in Rheumatology Fellow’s Cllinic
Sana Kang¹, George Gennaoui² and J. Patricia Dhar³, ¹Ascension St John Hospital, Chesterfield, MO, ²Ascension St. John Hospital, St. Clair Shores, MI, ³Ascension St. John Hospital and Wayne State University School of Medicine, Bloomfield Hills, MI
Background/Purpose: The US Center for Disease Control and Prevention recommends that adults ages 19 years and older, with immunocompromising conditions should receive a dose of…
Abstract Number: 1376 • ACR Convergence 2022
Eculizumab Is Safe as an Adjunctive Therapy in Systemic Lupus Erythematosus with Severe Refractory Nephritis with or Without Thrombotic Microangiopathy in Children
Maria Pereira¹, Angela Chun¹, Leigh Stubbs¹ and Marietta De Guzman², ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine/ Texas Children's Hospital, Houston, TX
Background/Purpose: Eculizumab is a monoclonal antibody that prevents the cleavage of C5, which inhibits the formation of the terminal complement complex. It is approved in…
Abstract Number: 1450 • ACR Convergence 2022
Impact of Time to Remission, Flares and Time on Immunosuppressives on the Estimated Glomerular Filtration Rate in Lupus Nephritis
KONSTANTINOS TSELIOS¹, Dafna Gladman², Jiandong Su³ and Murray Urowitz⁴, ¹McMaster University, Population Health Research Institute, Hamilton, ON, Canada, ²Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: Time to complete remission, subsequent flares and time on immunosuppressives after complete remission are major determinants of the progression to advanced chronic kidney disease…
Abstract Number: 1471 • ACR Convergence 2022
Trends and Predictors of Hospitalizations Due to Acute Myocardial Infarction in Systemic Lupus Erythematosus Patients
Izza Bazigh¹, Uzair Khan², Achint Patel³, Aaparna Singh³, Neha Ghalib³, Ghazi Farman⁴, Salman Muddassir³, Farrukh Zaidi⁵, Sami Mughni³ and Adam Grunbaum⁶, ¹HCA Florida Oak Hill Hospital, Spring Hill, FL, ²HCA Healthcare Florida / USF Morsani College of Medicine GME Consortium / Oak Hill Hospital, Odessa, FL, ³HCA Healthcare Florida / USF Morsani College of Medicine GME Consortium / Oak Hill Hospital, Spring Hill, FL, ⁴Rehman Medical College, Spring Hill, FL, ⁵HCA Healthcare Florida / USF Morsani College of Medicine GME Consortium / Oak Hill Hospital, Port Richey, FL, ⁶Gulf Coast Rheumatology, Trinity, FL
Background/Purpose: Cardiovascular events occur more frequently and with earlier onset in patients with Systemic Lupus Erythematosus (SLE) compared with healthy individuals. Several studies have concluded…
Abstract Number: 1592 • ACR Convergence 2022
Serious Infections in SLE- Incidence, Associated Factors, Impact and Trends over Two Decades
Rudrarpan Chatterjee, Sarit Sekhar Pattanaik, Durga P Misra, Vikas Agarwal, Able Lawrence and Amita Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Infections are a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). We assessed the incidence and risk factors for major infections…
Abstract Number: 1697 • ACR Convergence 2022
Measurements of Specific Activation Through the Lectin -or Classical Pathway of Complement in Patients with SLE
Anne Troldborg¹, Mads Lamm Larsen¹, Erik J.M. Toonen², Lisa Hurler³, Zoltan Prohaszka³, László Cervenak³, Annette Gudmann Hansen⁴ and Steffen Thiel⁴, ¹Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ²Hycult Biotech, Arnhem-Nijmegen, Netherlands, ³Semmelweis University, Budapest, Hungary, ⁴Aarhus University, Aarhus, Denmark
Background/Purpose: In systemic lupus erythematosus (SLE), the complement system is activated and commonly thought to occur through the classical pathway (CP) [1]. However, our previous…
Abstract Number: 1753 • ACR Convergence 2022
Temporal Trends of SLE Mortality Among Various Ethnic Categories Across the United States: 2001-to 2020 Analysis from WONDER Database
Ikwinder Preet Kaur¹, Harjot Jagdey², hasan Mirza³, Waqar Mughal⁴ and Pankaj Bansal⁵, ¹Rutgers/Monmouth Medical Center, Long branch, NJ, ²BronxCare Hospital, Bronx, NY, ³Berkshire Medical Center, Pittsfield, MA, ⁴DHQ teaching hospital, Gujrat, Pakistan, ⁵Mayo Clinic, Eau Claire, WI
Background/Purpose: Racial disparities in SLE have been well described. Blacks are disproportionately affected, and have a higher incidence, disease severity, and mortality compared to Whites,…
Abstract Number: 2058 • ACR Convergence 2022
Evidence on the Construct Validity of the Perceived Deficits Questionnaire Among Adult Patients with Systemic Lupus Erythematosus
Stefan Perera¹, Jiandong Su², Kathleen Bingham³, Mahta Kakvan¹, Maria Carmela Tartaglia⁴, Leslet Ruttan⁵, Joan Wither¹, May Choi⁶, Simone Appenzeller⁷, Dorcas Beaton⁸, Dennisse Bonilla², Patricia Katz⁹, Robin Green⁵, Michelle Barraclough¹⁰ and Zahi Touma², ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ³Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, ⁵University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁶Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁷Unicamp, Campinas, São Paulo, Brazil, ⁸Institute for Work & Health, Toronto, ON, Canada, ⁹UCSF, San Rafael, CA, ¹⁰Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is prevalent in SLE and negatively impacts social and occupational engagement. There is a need for a patient-reported outcome measure (PROM)…
Abstract Number: 2076 • ACR Convergence 2022
Unfavorable Outcomes Associated with Current Standard of Care in the Management of Patients with Systemic Lupus Erythematosus
Zahi Touma¹, Sheena Kayaniyil², Anna Parackal², Dennisse Bonilla¹, Jiandong Su¹, Christina Qian³, Sally Miller³, Shelagh Szabo³ and Shelly Chandran², ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ²AstraZeneca, Mississauga, ON, Canada, ³Broadstreet Health Economics & Outcomes Research, Vancouver, BC, Canada
Background/Purpose: The effectiveness of current standard of care treatment including corticosteroids (CS) in Systemic Lupus Erythematosus (SLE) is limited and has potential side-effects. Given the…
Abstract Number: 2096 • ACR Convergence 2022
Role of Cell-Bound Complement Fragments as Biomarkers to Determine Disease Activity in Patients with Systemic Lupus Erythematosus
Marcela Muñoz Urbano¹, Diana C. Quintero-González¹, Mauricio Rojas², Joaquín Rodelo¹, Alba Luz León Álvarez¹, Luis Gonzalez¹ and Gloria Vásquez³, ¹Universidad de Antioquia, Medellín, Colombia, ²Grupo de Inmunología Celular e Inmunogenética, GICIG, and Unidad de citometría de flujo, Sede de Investigación Universitaria, Universidad de Antioquia, Medellín, Colombia, ³Grupo de Inmunología Celular e Inmunogenética, GICIG and Grupo de Reumatología, Universidad de Antioquía, Medellín, Colombia
Background/Purpose: The prompt identification of patients with systemic lupus erythematosus (SLE) at risk of or in flare strongly influences the prognosis of the disease. Cell-bound…
Abstract Number: 2202 • ACR Convergence 2022
Association of Visit-based Retention and Receipt of Serologic Testing with Acute Care Use Among Young Adults with Lupus: A Medicare Cohort Study
Maria Schletzbaum¹, Brad C. Astor², W. Ryan Powell³, Shivani Garg⁴, Andrea Gilmore-Bykovskyi⁵, Joseph A. Kramer⁶, Amy J. Kind⁷ and Christie Bartels⁸, ¹University of Wisconsin School of Medicine and Public Health, Department of Population Health Sciences, Middleton, WI, ²University of Wisconsin School of Medicine and Public Health, Department of Medicine, Nephrology Division and Department of Population Sciences, Madison, WI, ³University of Wisconsin School of Medicine and Public Health, Center for Health Disparities Research, Thousand Oaks, CA, ⁴University of Madison, School of Medicine and Public Health, Madison, WI, ⁵University of Wisconsin School of Medicine and Public Health, Department of Emergency Medicine; and the Center for Health Disparities Research, Madison, WI, ⁶University of Wisconsin School of Medicine and Public Health, Department of Medicine & Center for Health Disparities Research,, Madison, WI, ⁷University of Wisconsin School of Medicine and Public Health, Department of Medicine, Geriatrics Division & Center for Health Disparities Research, Madison, WI, ⁸University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: While high quality lupus care is associated with less damage, the impact of care use patterns and care quality on lupus outcomes remains unclear,…
Abstract Number: 0106 • ACR Convergence 2022
A Systematic Review of Racial and Ethnic Disparities in Disease Related Outcomes Among Patients with SLE
Teresa Semalulu¹, Keerthana Pasumarthi¹, Kevin Zhao¹, Rauda AlDhaheri¹, Nadine Akbar², KAREN BEATTIE¹ and KONSTANTINOS TSELIOS³, ¹McMaster University, Hamilton, ON, Canada, ²Humber River Hospital and University of Toronto, Toronto, ON, Canada, ³McMaster University, Population Health Research Institute, Hamilton, ON, Canada
Background/Purpose: Racialized patients and ethnic minorities have worse outcomes in SLE. This is likely related to a complex interplay between genetic and non-genetic factors. Numerous…
Abstract Number: 0323 • ACR Convergence 2022
Identifying Distinct Phenotypes of Patients with Juvenile Systemic Lupus Erythematosus: Results from a Cluster Analysis by the Egyptian College of Rheumatology (ECR) Study Group
Nevin Hammam¹, Mohamed Bakrey Mahmoud², Aly Bakhiet³, Rasha El Owaidy⁴, Hend Abdel Nabi⁵, Ahmed M Elsaman⁶, Iman Khalifa⁷, Abeer M NourEl-Din⁸, Rawhya R ElShereef⁹, Eman Hassan¹⁰, Faten Ismail⁹, Iman I El-Gazzar¹¹, Abdelhafeez Moshrif¹², Noha M Khalil¹³, Marwa A Amer¹⁴, Hanan M Fathy¹⁵, Nancy Abdel Salam¹⁵, Samar Tharwat¹⁶, Mervat I Abd Elazeem¹⁷, Hanan M Fathi¹⁸ and Tamer A Gheita¹¹, ¹Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, PASADENA, CA, ²Higher Institute for Computer Science and Information Systems, 6th of October City, Cairo, Egypt, ³Higher Institute for Computer Science and Information Systems, 6th of October City, Assiut, Egypt, ⁴Pediatric Allergy, Immunology and Rheumatology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt, ⁵Pediatrics Department, Rheumatology and Nephrology Unit, Tanta University, Gharbia, Egypt, ⁶Rheumatology Department, Faculty of Medicine, Sohag University, Sohag, Egypt, ⁷Pediatrics Department, Rheumatology and Nephrology Unit, Helwan University, Cairo, Egypt, ⁸Pediatrics Department, National Research Centre (NRC), Cairo, Egypt, ⁹Rheumatology Department, Faculty of Medicine, Minia University, Minia, Egypt, ¹⁰Internal Medicine Department, Rheumatology Unit, Faculty of Medicine, Alexandria University, Alexandria, Egypt, ¹¹Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, ¹²Rheumatology Department, Faculty of Medicine, Al-Azhar University, Assiut, Egypt, ¹³Internal Medicine Department, Rheumatology Unit, Faculty of Medicine, Cairo University, Cairo, Egypt, ¹⁴Rheumatology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt, ¹⁵Pediatrics Department, Rheumatology and Nephrology Unit, Alexandria University, Alexandria, Egypt, ¹⁶Internal Medicine, Rheumatology Unit, Mansoura University, Dakahlia, Egypt, Dakahlia, Egypt, ¹⁷Rheumatology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt, ¹⁸Rheumatology Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt
Background/Purpose: Juvenile systemic lupus erythematosus (J-SLE) is a complex autoimmune disease characterized by a great heterogeneity in organs involvement. A better understanding of the organ…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].